Faron Pharmaceuticals appoints Dr. Juho Jalkanen as new CEO, as Dr. Markku steps down
TURKU, FINLAND: Faron Pharmaceuticals Ltd. (AIM: FARN), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological...
Juho Jalkanen appointed Chief Operating Officer of Faron Pharmaceuticals
TURKU, FINLAND: Faron Pharmaceuticals Ltd announced the appointment of Juho Jalkanen, M.D., Ph.D., as Chief Operating Officer of the Company. Dr. Jalkanen will continue to...
Faron receives €2.1 million loan, from Business Finland for Traumakine manufacturing
TURKU, FINLAND: Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, announced plans to initiate a new state of the art process for the manufacturing of...
Faron Pharmaceuticals selected for €2.5 million grant from European Innovation Council
TURKU, FINLAND: Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, has been selected to receive a €2.5 million grant from the European Innovation Council (EIC)...